Retreatment for hepatitis B after prior interferon therapy
Part of Digestive system, Infections clinical trials.
This trial tests a retreatment with pegylated interferon for people with chronic hepatitis B who have previously received interferon therapy and have seen their hepatitis B surface antigen (HBsAg) levels drop by at least half. The goal is to see if this retreatment can completely clear the virus from the blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have had chronic hepatitis B for at least 6 months.
- You have taken interferon before, but stopped at least 3 months ago.
- Your hepatitis B surface antigen (HBsAg) level was reduced by at least half with that prior treatment.
- Your current HBsAg level is 500 IU/mL or less, and it hasn't rebounded by more than 50% from your lowest level.
- If you are of childbearing age, you must use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This study tests whether a medicine called peginterferon can help lower the chance of hepatitis B coming back after you stop your current antiviral treatment. It may be an option for people with well-controlled hepatitis B and low levels of surface antigen.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This trial tests a new way to treat chronic hepatitis B in patients already taking antiviral medication. It combines a drug that helps the immune system fight the virus with another drug that boosts the immune response, aiming to improve chances of clearing the virus.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.